OncoMatch/Clinical Trials/NCT07632118
Radiotherapy With GX Regimen as Adjuvant Therapy for High-risk Patients Following Pancreatic Cancer Surgery
Is NCT07632118 recruiting? Yes, currently enrolling (Jul 2026). This Phase 3 trial studies GX group for pancreatic cancer.
Treatment: GX group — Pancreatic cancer is a highly fatal malignant tumor. Simple surgical operations can no longer meet the treatment needs of pancreatic cancer patients. Postoperative adjuvant chemotherapy has a significant effect, which can effectively prevent or delay tumor recurrence and prolong the overall survival period of pancreatic cancer patients. Based on this, many guidelines both at home and abroad actively recommend that pancreatic cancer patients receive adjuvant chemotherapy after surgery (if there are no contraindications). Radiotherapy is one of the most commonly used local treatment methods. It can be used as a neoadjuvant or adjuvant therapy to increase the tumor resection rate or reduce the recurrence rate, or as a treatment approach for locally unresectable pancreatic cancer to improve local control. After complete gross resection of pancreatic cancer, the role of radioadjuvant therapy has always been controversial, and its indications for use remain unclear. However, recent clinical studies using modern radiotherapy equipment and techniques have shown that an increasing amount of data indicates that radiotherapy can benefit in the treatment of neoadjuvant, adjuvant and locally advanced pancreatic cancer. Evidence supporting adjuvant radiotherapy after pancreatectomy remains scarce. Therefore, whether screening high-risk factor populations for adjuvant radiotherapy may improve the prognosis of pancreatic cancer is an important research.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Pancreatic Cancer
Disease stage
Excluded: Stage DISTANT METASTASIS
Grade: poorly differentiated
no evidence of distant metastasis confirmed by imaging; The pathology is poorly differentiated
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: radiotherapy
Had received radiotherapy ... before pancreatic tumor resection
Cannot have received: palliative chemotherapy
Had received ... palliative chemotherapy ... before pancreatic tumor resection
Cannot have received: targeted therapy
Had received ... other targeted ... therapy for anti-tumor treatment before pancreatic tumor resection
Cannot have received: immunotherapy
Had received ... immunotherapy for anti-tumor treatment before pancreatic tumor resection
Lab requirements
Blood counts
absolute neutrophil count ≥1.5×10^9/L, platelet count ≥80×10^9/L, hemoglobin ≥90g/L
Kidney function
Serum creatinine ≤1.5x ULN or creatinine clearance ≥60 ml/min (Cockcroft-Gault formula)
Liver function
Total bilirubin ≤1.5x ULN; AST and ALT ≤2.5x ULN
absolute neutrophil count ≥1.5×10^9, platelet count ≥80×10^9, hemoglobin ≥90g/L; Total bilirubin levels ≤1.5x ULN, AST and ALT ≤2.5x ULN. Serum creatinine ≤1.5x ULN or creatinine clearance ≥60 ml/min(Cockcroft-Gault formula)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07632118 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiotherapy, palliative chemotherapy, targeted therapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages